



Theratechnologies Announces Ibalizumab Inhibits HIV-2 In Vitro

July 6, 2020

Montreal, Canada – July 6, 2020 – Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, is pleased to announce that data presented at the 23rd International AIDS Conference virtual meeting, demonstrates that ibalizumab is active *in vitro* against group A and group B HIV-2.